【摘要】：當前治療抑郁癥的主流藥物有選擇性5羥色胺(5-HT)攝取抑制劑(SSRIs)和5-HT、去甲腎上腺素(NE)雙重再攝取抑制劑(SNRIs);臨床使用過程中存在起效緩慢、快感缺乏、認知功能低下和性功能障礙等缺陷;臨床前和臨床研究顯示,在SNRIs的基礎上加入多巴胺(DA)攝取抑制的5-HT/NE/DA三重再攝取抑制劑(SNDRIs)能夠改善目前藥物存在的治療缺陷。鹽酸安舒法辛為一種全新的SNDRIs,通過不均衡抑制5-HT/NE/DA再攝取發(fā)揮抗抑郁作用,預期在臨床應用上將具有起效快,改善患者快感缺乏和性功能障礙,增加認知、獎勵激勵驅(qū)動和目標導向行為等特點。
[Abstract]:The current mainstream drugs in the treatment of depression include selective serotonin (5-HT) uptake inhibitors (SSRIs) and 5-HTand norepinephrine (NE) dual reuptake inhibitor (SNRIs); There are some defects in clinical use, such as slow onset, lack of pleasure, low cognitive function and sexual dysfunction. Pre-clinical and clinical studies have shown that the addition of (SNDRIs), a triple reuptake inhibitor of 5-HT/NE/DA with dopamine (DA) uptake inhibition on the basis of SNRIs, can improve the current treatment defects. The antidepressant effect of ambrofaxine hydrochloride is a new kind of SNDRIs, which plays an antidepressant role through unbalanced inhibition of 5-HT/NE/DA reuptake. It is expected that it will take effect quickly in clinical application, improve the patients' pleasure deficiency and sexual dysfunction, and increase cognition. Incentive-driven and goal-oriented behavior and so on.
【作者單位】： 煙臺大學藥學院分子藥理和藥物評價省部共建教育部重點實驗室;綠葉制藥集團長效緩控釋和靶向制劑企業(yè)國家重點實驗室;
【基金】：國家“重大新藥創(chuàng)制”科技重大專項(2013ZX09402201)
【分類號】：R749.4

【參考文獻】

相關期刊論文 前1條

1 栗原雅直;葉惠珍;;抗抑郁藥[J];國外醫(yī)藥.合成藥.生化藥.制劑分冊;1986年03期

，

本文編號：2389254